<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>High Drug Costs</title>
    <meta content="L22MED" name="slug"/>
    <meta content="22" name="publication_day_of_month"/>
    <meta content="7" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Saturday" name="publication_day_of_week"/>
    <meta content="Editorial Desk" name="dsk"/>
    <meta content="14" name="print_page_number"/>
    <meta content="A" name="print_section"/>
    <meta content="4" name="print_column"/>
    <meta content="Opinion" name="online_sections"/>
    <docdata>
      <doc-id id-string="1216642"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Health Maintenance Organizations and Managed Care</classifier>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Medicaid</classifier>
        <person class="indexing_service">Braunstein, Richard B (Dr)</person>
        <classifier class="online_producer" type="types_of_material">Letter</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion/Letters</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicaid</classifier>
        <classifier class="online_producer" type="general_descriptor">Health Insurance and Managed Care</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20000722T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=980DEFD7173AF931A15754C0A9669C8B63" item-length="120" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>High Drug Costs</hl1>
      </hedline>
      <abstract>
        <p>Richard B Braunstein letter, commenting on July 15 editorial, says any Medicare drug benefit should not be controlled by health maintenance organizations</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>To the Editor:</p>
        <p>Any plan to put a Medicare drug benefit into the hands of health maintenance organizations (editorial, July 15) is flawed. I have patients with glaucoma who are covered by Medicare H.M.O.'s. Their disease had been under control, but they now face blindness because they can no longer pay for their medicines.</p>
      </block>
      <block class="full_text">
        <p>To the Editor:</p>
        <p>Any plan to put a Medicare drug benefit into the hands of health maintenance organizations (editorial, July 15) is flawed. I have patients with glaucoma who are covered by Medicare H.M.O.'s. Their disease had been under control, but they now face blindness because they can no longer pay for their medicines.</p>
        <p>That is because their H.M.O.'s cover only generic drugs, which are more than seven years old and no longer protected by patents. Would it be acceptable for me to discard the advances of the last seven years to help H.M.O.'s make profits? Congress should enact drug benefits that are administered without intermediaries.</p>
        <p>RICHARD B. BRAUNSTEIN, M.D.  San Carlos, Calif., July 16, 2000</p>
      </block>
    </body.content>
  </body>
</nitf>
